Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR

BACKGROUND: Inhibitors targeting immune checkpoint were proved effective in cancer immunotherapy, such as PD-1/PD-L1 blockade. The novel immune checkpoint TIGIT/PVR plays critical roles in suppressing the anti-tumor effects of CD8(+) T and NK cells, and dual blockade of TIGIT/PVR and PD-1/PD-L1 by a...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cell Commun Signal
Hlavní autoři: Zhou, Xiuman, Du, Jiangfeng, Wang, Hongfei, Chen, Chunxia, Jiao, Ling, Cheng, Xiangrui, Zhou, Xiaowen, Chen, Shaomeng, Gou, Shanshan, Zhao, Wenshan, Zhai, Wenjie, Chen, Junhui, Gao, Yanfeng
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2020
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7487564/
https://ncbi.nlm.nih.gov/pubmed/32894141
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12964-020-00638-2
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky